"Leishmaniasis, Visceral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.
| Descriptor ID |
D007898
|
| MeSH Number(s) |
C03.752.300.500.510
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Leishmaniasis, Visceral".
Below are MeSH descriptors whose meaning is more specific than "Leishmaniasis, Visceral".
This graph shows the total number of publications written about "Leishmaniasis, Visceral" by people in this website by year, and whether "Leishmaniasis, Visceral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leishmaniasis, Visceral" by people in Profiles.
-
Emerging strategies and challenges of molecular therapeutics in antileishmanial drug development. Int Immunopharmacol. 2023 Feb; 115:109649.
-
Curative efficacy of purified serine protease inhibitor PTF3 from potato tuber in experimental visceral leishmaniasis. Int Immunopharmacol. 2020 Aug; 85:106623.
-
Serine protease inhibitors rich Coccinia grandis (L.) Voigt leaf extract induces protective immune responses in murine visceral leishmaniasis. Biomed Pharmacother. 2019 Mar; 111:224-235.
-
Fabrication of 3-O-sn-Phosphatidyl-L-serine Anchored PLGA Nanoparticle Bearing Amphotericin B for Macrophage Targeting. Pharm Res. 2018 Feb 09; 35(3):60.
-
Chitosan coated PluronicF127 micelles for effective delivery of Amphotericin B in experimental visceral leishmaniasis. Int J Biol Macromol. 2017 Dec; 105(Pt 1):1220-1231.
-
Protective inflammatory response against visceral leishmaniasis with potato tuber extract: A new approach of successful therapy. Biomed Pharmacother. 2016 Oct; 83:1295-1302.
-
Bioinspired Calcium Phosphate Nanoparticles Featuring as Efficient Carrier and Prompter for Macrophage Intervention in Experimental Leishmaniasis. Pharm Res. 2016 11; 33(11):2617-29.
-
Targeting Ergosterol biosynthesis in Leishmania donovani: essentiality of sterol 14 alpha-demethylase. PLoS Negl Trop Dis. 2015 Mar; 9(3):e0003588.
-
Genetic analysis of Leishmania donovani tropism using a naturally attenuated cutaneous strain. PLoS Pathog. 2014 Jul; 10(7):e1004244.
-
Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani. Vaccine. 2013 Apr 08; 31(15):1905-15.